Nurix Therapeutics (NRIX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Nurix Therapeutics

NasdaqGM•Healthcare•Biotechnology

$25.15+0.32(0.01%)Pre-market

Market Cap

$2.83B

P/S

76.9x

P/B

7.0x

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

How this company scores

WeakMetricSide Score: 29/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Profitability (3/25).

Profitability3/25

Growth5/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Interest easily coveredNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 76.9x5y range 4.4x – 76.9x

Currently above its 17-quarter median.

P/B · 7.0x5y range 1.7x – 7.0x

Currently above its 17-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $2.83B

Metrics at a Glance

as of May 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $36.77M
Q. Revenue: $9.04M
TTM EBITDA: $-348.31M
TTM Op. Income: $-361.18M
Q. Op. Income: $-94.20M
TTM Net Income: $-341.35M
Q. Net Income: $-89.53M
EPS: $-0.81
Shares Out.: $111.08M

$36.77M in TTM revenue declined 58.4% YoY, reaching $9.04M last quarter. TTM EBITDA of $-348.31M and TTM operating income of $-361.18M show growth is flowing through to the bottom line. However, net income is negative at $341.35M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 2 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -1016.8%
Op. Margin: -1041.7%
Net Margin: -990.1%

Op. margin of -1041.7% is down 932.1% YoY — costs are rising relative to revenue. Net margin at -990.1% Over the past year, operating margin is down 850% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 76.9x
P/B Ratio: 7.0x

P/S of 76.9x and P/B of 7.0x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $535.54M
Cash: $67.69M
Long-Term Debt: N/A
Book Value: $402.63M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-96.57M
TTM Free Cash Flow: $-304.53M
FCF Margin: -828.3%
FCF / Net Income: 0.9

TTM FCF of $-304.53M on $-96.57M in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 7 consecutive quarters — a weakening trend.